Key Takeaways Madrigal posted a Q3 loss of $5.08 per share, wider than the expected $1.98 loss.Rezdiffra sales hit $287.3M, surpassing estimates and fueling strong investor response.EU approval and new licensing moves reinforce Madrigal's expanding MASH franchise.Madrigal Pharmaceuticals (MDGL) reported third-quarter 2025 loss of $5.08 per share, wider than the Zacks Consensus Estimate of a loss of $1.98. In the year-ago quarter, the company had incurred a loss of $4.92 per share.During the quarter, the com ...

The company has also made strategic moves to strengthen its pipeline and market position. Madrigal entered a global licensing agreement with CSPC Pharma to incorporate an oral GLP-1 into its offerings. Additionally, a new Orange Book listed patent for Rezdiffra extends its protection until 2045. The launch of Rezdiffra in Germany following European Commission approval further expands its market reach. Financially, Madrigal has a negative P/E ratio of -35.13, reflecting its current lack of profitability. How ...

Washington, D.C. 20549 _________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33277 _________________________ MADRIGAL PHARMACEUTICALS, INC. (Exact name of r ...

Madrigal Pharmaceuticals (NasdaqGS:MDGL) Q3 2025 Earnings Call November 04, 2025 08:00 AM ET Company ParticipantsAkash Tewari - Global Head of Biopharmaceutical ResearchAndrea Newkirk - VP of Biotechnology Equity ResearchBill Sibold - CEOEmma Gutstein - Equity Research AssociateMichael DiFiore - Managing Director of Biotechnology and Pharmaceuticals Equity ResearchMardi Dier - CFOTina Ventura - CIRODavid Soergel - CMO and EVPConference Call ParticipantsRitu Baral - Managing Director and Senior Biotechnology ...

Madrigal Pharmaceuticals (NasdaqGS:MDGL) Q3 2025 Earnings Call November 04, 2025 08:00 AM ET Company ParticipantsAkash Tewari - Global Head of Biopharmaceutical ResearchAndrea Newkirk - VP of Biotechnology Equity ResearchBill Sibold - CEOEmma Gutstein - Equity Research AssociateMichael DiFiore - Managing Director of Biotechnology and Pharmaceuticals Equity ResearchMardi Dier - CFOTina Ventura - CIRODavid Soergel - CMO and EVPConference Call ParticipantsRitu Baral - Managing Director and Senior Biotechnology ...

Madrigal Pharmaceuticals (NasdaqGS:MDGL) Q3 2025 Earnings Call November 04, 2025 08:00 AM ET Speaker5Good morning, and thank you for standing by. Welcome to the Madrigal Pharmaceuticals third quarter 2025 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. As a reminder, today's conference call is being recorded. I'd like to introduce Ms. Tina Ventura, Chief Investor Relations Officer. Please go ahea ...

NASDAQ: MDGL © 2025 Madrigal Pharmaceuticals, Inc. All rights reserved. Forward-looking Statements This presentation includes "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are based on Madrigal's beliefs and assumptions and on information currently available to it but are subject to factors beyond its control. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regar ...

Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates CONSHOHOCKEN, Pa., Nov. 4, 2025 – Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2025 financial results and provides corporate updates. Bill Sibold, Chief Executive Officer of Madrigal, stated: "Six quarters into Rezdiffra's launch, we continue to execu ...

Third-quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 millionAs of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent for Rezdiffra providing protection into 2045 Launched Rezdiffra in Germany following European Commission approval Reports cash, cash equivalents, restricted cash and marketable securities of $1.1 billion as of Sept. 30, 2025Company to host conference call today, Nov ...

公司业绩预期 - 华尔街预计Madrigal在截至2025年9月的季度营收将实现同比增长，并伴随盈利改善 [1] - 公司预计季度每股亏损为1.99美元，同比改善59.6% [3] - 公司预计季度营收为2.4915亿美元，同比增长300.8% [3] 预期修正趋势 - 过去30天内，该季度共识每股收益预期被上调了10.44%至当前水平 [4] - 最准确预期高于Zacks共识预期，表明分析师近期对公司盈利前景转为乐观 [12] - 这导致公司的盈利ESP为+27.84% [12] 盈利惊喜预测 - 盈利ESP理论上指示实际盈利与共识预期的可能偏差 [9] - 当盈利ESP为正值且结合Zacks排名第1、2或3时，是盈利超预期的强预测指标 [10] - 具有此组合的股票有近70%的概率实现正面惊喜 [10] - Madrigal目前Zacks排名为第2级 [12] - 该组合表明Madrigal极有可能超越共识每股收益预期 [12] 历史惊喜记录 - 上一报告季度，Madrigal预计每股亏损3.48美元，实际亏损1.90美元，实现惊喜+45.40% [13] - 在过去四个季度中，公司四次超越共识每股收益预期 [14] 行业同业比较 - 同业公司BioCryst Pharmaceuticals预计季度每股收益为0.07美元，同比增长200% [18] - 该公司预计季度营收为1.6115亿美元，同比增长37.6% [19] - 过去30天内，其共识每股收益预期被下调4.8% [19] - 该公司盈利ESP为+17.12%，结合其Zacks排名第3级，表明其很可能超越盈利预期 [20] - 在过去四个季度中，该公司两次超越共识每股收益预期 [20]